Aduro Biotech Inc

Aduro Biotech — Investor Presentation (January 2016)

39 slides from Aduro Biotech's investor presentation, Jan 11, 2016

  1. Slide 1: Company Overview January 2016

    Company Overview January 2016 Exhibit 99.1

  2. Slide 2: Disclaimer: Special Note Regarding Forward-Looking Statements

    Disclaimer Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. (“Aduro”) that are not historical fa

  3. Slide 3: Aduro Highlights

    Aduro Highlights Three diverse and versatile immunotherapy platforms LADD – novel, live-attenuated Listeria platform to deliver tumor antigens Survival benefit demonstrated in randomized Phase 2 trial in pancreatic cancer trial 94% disease control rate in Phase 1b mesothelioma trial Two Phase 1 tria

  4. Slide 4: 2015 Accomplishments

    2015 Accomplishments Corporate achievements Raised ~$175 million in Series D and IPO Signed $750M CDN collaboration with Novartis targeting STING pathway in oncology Acquired BioNovion, a monoclonal antibody company; launched Aduro Biotech Europe Clinical achievements Published Phase 2a pancreatic c

  5. Slide 5: Aduro's Place in Cancer Therapy

    Aduro’s Place in Cancer Therapy Physicians and scientists are changing the way they think about the biology and treatment of cancer Emerging paradigm: Combinations of conventional and novel immuno-oncology therapies aimed to improve cancer patient survival Aduro has the potential to assume an import

  6. Slide 6: Enhancing Therapeutic Strength through Combinations

    Enhancing Therapeutic Strength through Combinations Chemo- therapy Immune Agonists Radio- therapy Checkpoint Inhibitors Targeted Therapies GVAX / Cellular Therapies LADD CDN B-select mAbs Breadth of Potential Combinations with Conventional and Novel Therapies ADURO PLATFORMS 6

  7. Slide 7: LADD Platform: Promising Vector to Induce Innate & Adaptive Immunity

    LADD Platform: Promising Vector to Induce Innate & Adaptive Immunity Proprietary gene engineering for safety and efficacy Deletion of two virulence genes substantially reduces disease-causing properties Multivalent antigen cassettes for antigen expression Favorable safety profile in trials to date I

  8. Slide 8: LADD Platform Stimulates Innate Immunity Responses and Antigen-specific T Cell Responses

    LADD Platform Stimulates Innate Immunity Responses and Antigen-specific T Cell Responses

  9. Slide 9: CDN Platform: Off-the-Shelf Patient Specific Immunity

    CDN Platform: Off-the-Shelf Patient Specific Immunity Targets and activates STING – central mediator of innate immunity Proprietary synthetic CDN structures Activate all known human STING receptors Synthetic compounds more potent than natural STING ligands Significant anti-tumor activity in pre-clin

  10. Slide 10: CDNs Activate Innate & Adaptive Immunity through STING

    CDNs Activate Innate & Adaptive Immunity through STING

  11. Slide 11: B-select Monoclonal Antibodies

    Soluble Ligands B-select Monoclonal Antibodies Targets First- or Best-in-Class Agonist and Antagonist mAbs Confidential Blocking antibodies APRIL

  12. Slide 12: Aduro's Development Pipeline

    Program Indication Combination Discovery / Preclinical Phase 1 Phase 2 Phase 3 LADD Programs CRS-207 Pancreatic GVAX Pancreatic GVAX+αPD-1 Mesothelioma Chemo Ovarian Epacadostat ADU-623 Glioblastoma None ADU-741 Prostate TBD ADU-214 Lung Multiple / TBD CDN Programs ADU-S100 Palpable tumors Adjuvant

  13. Slide 13: Clinical Programs CRS-207: LADD Strain Expressing Mesothelin Tumor Antigen

    Clinical Programs CRS-207: LADD Strain Expressing Mesothelin Tumor Antigen

  14. Slide 14: CRS-207: Pancreatic Cancer

    CRS-207: Pancreatic Cancer Phase 2a: CRS-207 + GVAX (Completed) Demonstrated survival benefit vs. GVAX Pancreas alone Favorable safety profile to date Continue to treat and monitor long-term survivors Phase 2b: CRS-207 + GVAX (Fully Enrolled) Primary endpoint: Overall survival superiority vs. chemot

  15. Slide 15: CRS-207: Pancreatic Cancer Promising Phase 2a Results with Long-Term Survivors

    Long-term Tail Time (Months) on Study Survival Probability CRS-207: Pancreatic Cancer Promising Phase 2a Results with Long-Term Survivors 2:1 24 mo. follow-up 24 mo. follow-up R CRS-207 GVAX Pancreas Subjects may continue on additional courses of treatment if clinically stable Median OS 6.1 vs. 3.9

  16. Slide 16: CRS-207: Pancreatic Cancer Comprehensive Phase 2b Trial Fully Enrolled

    CRS-207: Pancreatic Cancer Primary endpoint: Overall survival in Arm A vs Arm C (third line) Statistical design: 80% power, hazard ratio=0.67, α=0.15 (one-sided) Secondary endpoints include: Safety, progression-free survival, tumor response rate and quality of life Top line data expected late Q2 201

  17. Slide 17: CRS-207: Pancreatic Cancer Combination with Checkpoint Inhibitors

    24 mo. follow-up CRS-207: Pancreatic Cancer Primary endpoint: Overall survival Secondary endpoints: Clinical response and safety Interim data expected to be reported in 2H 2016 Investigator-sponsored study supported by Aduro, Bristol-Myers Squibb, Stand Up to Cancer, PanCAN/AACR and Lustgarten Found

  18. Slide 18: CRS-207: Pancreatic Cancer Phase 3 Planning and Manufacturing

    CRS-207: Pancreatic Cancer Trial design concept Global study in metastatic pancreatic cancer patients who received prior chemotherapy Opportunity to evaluate as a second-line therapy Primary endpoint: Overall survival Final design based on ECLIPSE results Finalize plan in 2H 2016 Technology transfer

  19. Slide 19: CRS-207: Mesothelioma

    CRS-207: Mesothelioma Phase 1b: Front line combination of CRS-207 and chemotherapy (Fully Enrolled) Single arm trial in combination with SOC chemotherapy Safety and efficacy data updated at ESMO 2015 59% partial response rate, 94% disease control rate in front line patients Sites remain open for con

  20. Slide 20: CRS-207: Mesothelioma Phase 1b Clinical Trial

    CRS-207: Mesothelioma Primary endpoints: Safety and immune response Secondary endpoints: Tumor response, time to progression, progression-free survival, overall survival, immune analyses, tumor marker kinetics Survival results expected in 1H 2016 Phase 1b Clinical Trial in Mesothelioma Patients may

  21. Slide 21: CRS-207: Mesothelioma Best Overall Response of Target Lesions

    CRS-207: Mesothelioma Best Overall Response of Target Lesions 85% of subjects experienced tumor shrinkage ESMO 2015

  22. Slide 22: CRS-207 + Epacadostat: Ovarian Cancer

    CRS-207 + Epacadostat: Ovarian Cancer Planned Phase 1/2 Trial Design 1:1 R Platinum‑resistant Ovarian, Fallopian, or Peritoneal Cancer Patients Part 1 (Up to 42 patients) Safety & Biomarker Evaluation Part 2 (Up to 86 patients) Primary Objective: Dose Selection Primary Objective: ORR and PFS Patient

  23. Slide 23: Cyclic Dinucleotides (CDN) Small Molecules Targeting STING

    Cyclic Dinucleotides (CDN) Small Molecules Targeting STING (Stimulator of Interferon Genes)

  24. Slide 24: First-in-Human Clinical Study to Target STING

    First-in-Human Clinical Study to Target STING ADU-S100 Clinical Trial in H1 2016 ADU-S100 induces innate immunity through STING STING is the critical receptor to activate immune cells including dendritic cells in the tumor microenvironment IT injection of ADU-S100 leads to an “inflamed” tumor phenot

  25. Slide 25: CDN: Encouraging Preclinical Data

    CDN: Encouraging Preclinical Data Activity in B16 Melanoma Tumor Model Significantly Better than TLR Ligands Groups: (N=8) Proprietary CDN versus TLR Ligands Proprietary CDN versus Naturally Occurring Injections P<.05 Groups: (N=8) Injections P<.05

  26. Slide 26: CDN: Protective Immunity in Preclinical Model

    CDN: Protective Immunity in Preclinical Model B16 subcutaneous injection in the flank (Day 0) followed by IV injection (Day 7) ADU-S100 IT treatment course (Days 14, 17, 21) on primary flank tumor Immunity in Lung Metastases Following IT Injection of Primary Tumor * * * Groups: (N=8) B16 Tumor Model

  27. Slide 27: ADU-S100: Solid Tumors or Lymphomas

    ADU-S100: Solid Tumors or Lymphomas Two-part study to assess the safety/tolerability in patients with cutaneously accessible, treatment-refractory primary or metastatic solid tumors or lymphomas Part 1: dose escalation in cohorts of 3-6 pts Part 2: dose expansion arms to better characterize safety/e

  28. Slide 28: CDN Breadth of Potential Product and Combination Opportunities

    Cyclic Dinucleotides (CDN) Breadth of Potential Product and Combination Opportunities CDN Intratumoral Delivery Oncology Systemic Delivery Oncology Antibody Conjugation Oncology Vaccine Adjuvant Infectious Disease STING Blockade Autoimmunity / Inflammation Vaccine Adjuvant Oncology Not Partnered

  29. Slide 29: Acquisition, Collaborations and Intellectual Property

    Acquisition, Collaborations and Intellectual Property

  30. Slide 30: Acquisition of BioNovion in 2015

    Acquisition of BioNovion in 2015 Immunotherapy pipeline includes assets that inhibit clinically validated immune checkpoint pathways May be used alone or in combination with the LADD and CDN platforms to increase immunotherapy potency and durability Broad library of therapeutic antibodies APRIL inhi

  31. Slide 31: Robust Collaboration with Janssen Pharmaceuticals

    Robust Collaboration with Janssen Pharmaceuticals Initiated two Phase 1 trials in lung and prostate cancer using LADD candidates (ADU-214 and ADU-741) Prostate Cancer Global License to ADU-741 and permitted derivatives $12M upfront $365M total upfront and potential milestones Tiered mid single-digit

  32. Slide 32: Major STING Oncology Collaboration with Novartis

    Major STING Oncology Collaboration with Novartis Structure Worldwide covering STING agonists from either company for oncology Joint research and development Aduro leads U.S. commercialization and books U.S. sales NVS leads ex-U.S. commercialization and books ex-U.S. sales Financial Terms $200M upfro

  33. Slide 33: Aduro Maintains Global Rights to Broad Portfolio

    Aduro Maintains Global Rights to Broad Portfolio CRS-207 (mesothelin antigen) Pancreatic cancer: Breakthrough Therapy designation with GVAX Pancreas Mesothelioma: Strong Phase 1b response data Additional mesothelin-expressing cancers: i.e. ovarian cancer ADU-623 (NYESO-1 and EGFRvIII antigens) Gliob

  34. Slide 34: Intellectual Property and Exclusivity in the United States

    Intellectual Property and Exclusivity in the United States Global Rights (inclusive of in-licensed patents) >200 issued composition and methods patents >50 pending applications Extensive Patent Portfolio and Favorable Regulatory Designations Technology Nominal Expiration Market and Data Exclusivity

  35. Slide 35: Financials and Milestones

    Financials and Milestones

  36. Slide 36: 2015 Financials

    2015 Financials Cash & cash equivalents as of 9/30/2015 $448.4 M Operating expenses through 9/30/2015 $55.0 M Shares outstanding as of 9/30/2015 62.3 M Strong Financial Position

  37. Slide 37: Significant Catalysts Expected in 2016

    Q1 2016 Q2 2016 H1 2016 H2 2016 CRS-207 for Pancreatic Cancer ECLIPSE (GVAX Pancreas + CRS-207) Report Phase 2b top line results STELLAR (nivolumab + GVAX Pancreas + CRS-207) Report Phase 2b interim analysis Finalize Phase 3 trial design CRS-207 for Mesothelioma Report final Phase 1b top line result

  38. Slide 38: Aduro Highlights

    Aduro Highlights Three diverse and versatile immunotherapy platforms LADD – novel, live-attenuated Listeria platform to deliver tumor antigens Survival benefit demonstrated in randomized Phase 2 trial in pancreatic cancer trial 94% disease control rate in Phase 1b mesothelioma trial Two Phase 1 tria

  39. Slide 39: Company Overview January 2016

    Company Overview January 2016

Aduro Biotech — Investor Presentation (January 2016) on 6ix